| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C59H113NO5 |
| Purity | |
| SMILES | |
| Form | Viscous Liquid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
CL4H6 is a pH-sensitive cationic lipid that serves as the main component of lipid nanoparticles (LNPs) that can be used to target and deliver siRNA, inducing a potent gene-silencing response[1][2]. It is supplied as a colorless to light yellow viscous liquid (C59H113NO5, MW 916.53) at 98.32% purity.
Physical & Chemical Properties
| CAS Number | 2256087-35-9 |
|---|---|
| Molecular Formula | C59H113NO5 |
| Molecular Weight | 916.53 g/mol |
| Purity | 98.32% |
| Appearance | Viscous Liquid |
| Color | Colorless to light yellow |
| SMILES | CCCN(CCC)CCCCC(CCCCCCOC(CCCCCCC/C=C\CCCCCCCC)=O)(O)CCCCCCOC(CCCCCCC/C=C\CCCCCCCC)=O |
| Signaling Pathway | Metabolic Enzyme/Protease |
| Solubility | In Vitro: DMSO: 100 mg/mL (109.11 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Pure form: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 100 mg/mL (109.11 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | 2.5 mg/mL (2.73 mM); suspension; requires sonication |
| How to prepare | Gives a suspension at 2.5 mg/mL. The suspension is suitable for oral and intraperitoneal dosing. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 2
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 2.5 mg/mL (2.73 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
CL4H6 targets hepatocytes potently and mediates endosomal escape, allowing safe and efficient delivery to human conjunctival fibroblasts of a myocardin-related transcription factor/serum response factor (MRTF/SRF)-B siRNA[2].
In Vivo
In a human tumor xenograft model in nude mice, the optimized siRNA-loaded CL4H6-LNPs are taken up selectively and efficiently by tumor-associated macrophages (TAMs) and show strong gene silencing activity there. Silencing of STAT3 and HIF-1α produces the anti-tumor therapeutic response, which comes with an increased level of infiltrated macrophages (CD11b+ cells) in the tumor-microenvironment (TME) and a tendency toward a higher concentration of M1 macrophages (CD169+ cells). Treatment also reverses the pro-tumorous functions of TAMs, mainly angiogenesis and tumor cell activation, as shown by decreased expression of the related genes at the mRNA level[1].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Reprogramming tumour-associated macrophages in breast cancer via si-FOXM1-loaded lipid nanoparticles enhances immune checkpoint inhibitor efficacy. Br J Pharmacol 2026 Jun;183(11):3049-3073. PMID: 41723880
